focus -WSS

focus

author：leisure time 2025-09-30 14:59:08 - browse：41545

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Senate committee scrutinizes Medicare Advantage brokers

explore

WSS

CEOs share strategies for surviving biotech slump

Fed up with FDA, ALS advocates consider a take

NIH confirmation hearing shows politicization of research

Assistant physicians can help address the primary care shortage

Senate bill would ban some hospital facility fees

STAT Summit: Michael J. Fox on progress in Parkinson's research

focus

focus

focus

Virginia high school admissions case could be legal follow

Senate bill would ban some hospital facility fees

Sports medicine is finally prioritizing gender equality

Hospital price transparency does save money, advocate argues

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How the messy conversation about Dolly changed bioethics

Psychedelics group wrestles with new pharma identity

Will Ozempic

In age of alternative facts, a scholarly course on calling out crap

Neurocrine congenital adrenal hyperplasia trial succeeds

Wikipedia

Pharmacists can make shortage drugs, but at what cost?

Beam Therapeutics to lay off 20% of its staff, re

David Liu startup to focus on CRISPR delivery

Fed up with FDA, ALS advocates consider a take

What happened to the House vote on health price transparency?

Eli Lilly expects to double planned employment in Boston center

explore

hotspot

focus

focus